Sell4

HCA Healthcare, Inc.

HCA

Total Value

$44.8M

Net $15.9M sold

Filing Date

Nov 6, 2026

8 transactions

Sales

$15.9M

8 transactions

Trade Summary

On Nov 4, 2026 through Nov 6, 2026, Foster Jon M, Insider, sold $44.8M of HCA Healthcare, Inc. (HCA) across 8 transactions. The filing covers Common Stock and reflects net selling of $15.9M. Reported prices ranged from $145.24 to $514.07. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

HCA daily price with the insider's sale marked at $500.98.

Sold near the 6-month high · about level with today's price.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Foster Jon M
Role: Insider
Location: NASHVILLE, TN

Filing Details

Filing Date: Nov 6, 2026
Transaction Date: Nov 4, 2026
Accession Number: 0001193125-26-452037
Form Type: 4
Net Trading Amount: -$15.9M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Nov 4, 2026	Common Stock	10,000	$514.07	Sale	$5.1M
Nov 4, 2026	Common Stock	35,880	$145.24	Exercise	$5.2M
Nov 4, 2026	Common Stock	20,309	$510.70	Tax Withholding	$10.4M
Nov 4, 2026	Common Stock	16,142	$503.52	Other	$8.1M
Nov 6, 2026	Common Stock	890	$498.97	Sale	$444.1K
Nov 6, 2026	Common Stock	1,684	$498.00	Sale	$838.6K
Nov 6, 2026	Common Stock	1,066	$496.92	Sale	$529.7K
Nov 6, 2026	Common Stock	2,692	$495.85	Sale	$1.3M
Nov 6, 2026	Common Stock	7,595	$494.91	Sale	$3.8M
Nov 6, 2026	Common Stock	6,302	$493.58	Sale	$3.1M
Nov 6, 2026	Common Stock	1,484	$491.98	Sale	$730.1K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Nov 4, 2026	HCA derivative	35,880	$145.24	Exercise	$5.2M

Want live alerts when Foster Jon M trades again?

Download Insider Trades to track HCA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F2)Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
(F3)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F4)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F5)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F6)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F7)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F8)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F9)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(F10)The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster Jon M

(Last)

(First)

(Middle)

ONE PARK PLAZA

(Street)

NASHVILLE

37203

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HCA Healthcare, Inc. [ HCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and COO

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/04/2026		S		10,000	D	$514.0698⁽¹⁾	0	D
Common Stock	11/04/2026		M		35,880	A	$145.24	35,880	D
Common Stock	11/04/2026		F		20,309	D	$510.7	15,571	D
Common Stock	11/04/2026		J⁽²⁾		16,142	D	$503.525	51,453	I	By JMF Trust (Spouse and Robert Nagel, Co-Trustees)
Common Stock	11/06/2026		S		890	D	$498.971⁽³⁾	30,823⁽²⁾	D
Common Stock	11/06/2026		S		1,684	D	$497.9984⁽⁴⁾	29,139	D
Common Stock	11/06/2026		S		1,066	D	$496.9199⁽⁵⁾	28,073	D
Common Stock	11/06/2026		S		2,692	D	$495.8541⁽⁶⁾	25,381	D
Common Stock	11/06/2026		S		7,595	D	$494.9145⁽⁷⁾	17,786	D
Common Stock	11/06/2026		S		6,302	D	$493.5795⁽⁸⁾	11,484	D
Common Stock	11/06/2026		S		1,484	D	$491.9817⁽⁹⁾	10,000	D
Common Stock								72,308	I	By LCF Trust (Reporting Person, Trustee)
Common Stock								19,985	I	By JMF Family Trust (Spouse, Trustee)
Common Stock								11,566	I	By 2025 GRAT
Common Stock								13,062	I	By 2026 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Appreciation Right	$145.24	11/04/2026		M			35,880	⁽¹⁰⁾	01/29/2030	Common Stock	35,880	$0.00	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.87 to $514.24, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. Pursuant to a power of substitution, on November 4, 2026, the reporting person transferred 16,142 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $503.525 (the average of the high and low prices of shares of common stock of the Issuer on November 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the reporting person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the reporting person as indirectly owned. The reporting person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.54 to $499.53, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.55 to $498.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.55 to $497.51, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.49 to $496.47, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $494.43 to $495.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $492.50 to $494.42, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $491.46 to $492.36, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.

	/s/ Kevin A. Ball, Attorney-in-Fact	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001193125-26-452037.

HCA Healthcare, Inc.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Foster Jon M trades again?

Footnotes

SEC Form 4

SEC Filing

Price at the Time of the Trade

SEC Form 4